Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company fo...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $90 pr...
Goldman Sachs analyst Paul Choi maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $55 to ...
TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $60 to...
Raymond James analyst Martin Auster reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target ...
Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price targ...
Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from...
Truist Securities analyst Danielle Brill reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target fr...
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(...
